As reported on September 7th by various media outlets， UK researchers have recently developed a simple electroencephalogram (EEG) test method called “Fastball，” capable of detecting signs of memory impairment years before the clinical symptoms of Alzheimer’s disease manifest， thereby facilitating earlier diagnosis and intervention.
Researchers from the University of Bath and the University of Bristol have published a paper in the journal *Brain Communications* detailing this new testing approach. The test identifies early memory issues in individuals with mild cognitive impairment by recording brain electrical activity as participants view a series of images. Mild cognitive impairment is considered a significant precursor for the future development of Alzheimer’s disease in some individuals.
Unlike traditional methods， this test is a passive EEG examination lasting approximately 3 minutes. Participants are not required to follow instructions or recall information; instead， the test relies on monitoring automatic brain responses to assess cognitive function. This design makes the test more objective and user-friendly， potentially assisting individuals who cannot undergo diagnostic assessments under clinical conditions for various reasons. The passive nature of the test is a significant advantage， as it reduces the cognitive load on the participant and minimizes potential variability introduced by engagement or effort.
In recent years， several breakthrough drugs for Alzheimer’s disease have proven effective in clinical trials at slowing disease progression. However， clinical research consistently demonstrates that these medications are most beneficial when administered in the early stages of the disease. Consequently， early diagnosis has become paramount. Despite this， a substantial number of patients miss crucial opportunities for intervention and care due to delayed diagnosis. In this context， the introduction of simple tools like the “Fastball” test is met with considerable hope and expectation.
Researchers state that commonly used diagnostic tools often miss the early， latent phase of Alzheimer’s disease， which can span 10 to 20 years. The “Fastball” test， characterized by its speed and passive detection， can identify signs of memory decline earlier and more objectively. The researchers further indicated that this test can be conducted in general practice clinics， memory clinics， or even in home environments， making it possible to implement broader screening and monitoring for Alzheimer’s disease using low-cost， easily accessible technology. The potential for widespread adoption in primary care settings could revolutionize how Alzheimer’s is managed， shifting the focus from late-stage symptom management to early prevention and treatment.
